Literature DB >> 23087420

The MANTA 1-year results: the anti-VEGF debate continues.

Justis P Ehlers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23087420     DOI： 10.1136/bjophthalmol-2012-302489

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  3 in total

1.  Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions.

Authors:  C Biagi; V Conti; N Montanaro; M Melis; E Buccellato; M Donati; A Covezzoli; R Amato; L Pazzi; M Venegoni; A Vaccheri; D Motola
Journal:  Eur J Clin Pharmacol       Date:  2014-09-20       Impact factor: 2.953

2.  Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series.

Authors:  Ahmad Mirshahi; Alireza Lashay; Hamid Riazi-Esfahani; Nazanin Ebrahimiadib; Hassan Khojasteh; Fariba Ghassemi; Fatemeh Bazvand; Alireza Khodabande; Ramak Roohipour; Elias Khalili Pour; Hooshang Faghihi
Journal:  J Ophthalmic Vis Res       Date:  2021-01-20

3.  Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario.

Authors:  Prashant Jain; Jay Sheth; Giridhar Anantharaman; Mahesh Gopalakrishnan
Journal:  Indian J Ophthalmol       Date:  2017-07       Impact factor: 1.848
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.